SAN DIEGO, May 31, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Jefferies 2012 Global Healthcare Conference in New York. The presentation is scheduled for Wednesday, June 6th at 9:30 a.m. EDT at the Grand Hyatt New York. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's website at www.orexigen.com. A replay will be available for 14 days after the event.
About Orexigen® Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Contrave cardiovascular outcomes trial which the company plans to initiate this quarter. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.
Media Contact: McDavid Stilwell
Denise PowellVP, Corporate Communications and Business Development
|SOURCE Orexigen Therapeutics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved